David Alan Rizzieri

My research interests focus on the care of patients with hematologic malignancies, both with and without the use of bone marrow or stem cell transplantation. I focus my research efforts on new approaches to manipulate minimal residual disease.

Recent endeavors have included:

1. Phase one trials with novel anti-cancer agents targeting aurora kinases, tyrosine kinases, mtor, VEGF, and raf/ras pathways 
2. New monoclonal antibodies targeting tumor stroma rather than cellular antigens 
3. Investigating new antibody targets, i.e. CD123, endoglin, or tenascin for hematologic malignancies 
4. Aggressive therapy and transplantation for mantle cell lymphoma 
5. Antiangiogenesis therapy for patients with NHL 
6. Nonablative allogeneic transplantation therapy with matched or mismatched donors followed by immune modulation